Previous 10 | Next 10 |
2024-01-07 17:18:52 ET More on Akoya Biosciences, Exact Sciences, etc. Guardant Health: Vast Market Opportunity, Challenging Valuation Illumina: The Divestiture Of Grail Could Unlock Significant Shareholder Value Illumina: Conditions Are Met For A Rebound Nan...
CARLSBAD, Calif., Jan. 07, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announces select preliminary unaudited financial results for the full year ended December 31, 2023, and reaffirms its full-year 2023 financial guidance. ...
2023-11-20 08:37:05 ET Exagen Inc. (XGN) Q3 2023 Earnings Conference Call November 13, 2023, 04:30 PM ET Company Participants Ryan Douglas - IR John Aballi - President and CEO Kamal Adawi - CFO Conference Call Participants Kyle Mikson - Canaccord Genu...
2023-11-17 16:21:55 ET More on Exagen Seeking Alpha’s Quant Rating on Exagen Historical earnings data for Exagen For further details see: Exagen files for a $150M mixed shelf offering
2023-11-13 16:28:54 ET More on Exagen Seeking Alpha’s Quant Rating on Exagen Historical earnings data for Exagen Financial information for Exagen For further details see: Exagen GAAP EPS of -$0.31 beats by $0.15, revenue of $13.4M beats by $3.07M
SAN DIEGO, California, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2023. Recognized total revenue of $13.4 million for the third quarter of 2023. ...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Exagen Inc. (XGN) is expected to report $-0.5 for Q3 2023
2023-11-09 18:23:40 ET More on Exagen Seeking Alpha’s Quant Rating on Exagen Historical earnings data for Exagen Financial information for Exagen For further details see: Exagen licenses lupus nephritis biomarkers from Johns Hopkins
SAN DIEGO, California, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, and Johns Hopkins University jointly announced today the execution of an exclusive license agreement. Exagen will focus on the development of novel pat...
News, Short Squeeze, Breakout and More Instantly...
CARLSBAD, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2024. First Quarter Highlights: Recognized total revenue of $14.4 million in the ...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...
CARLSBAD, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended March 31, 2024, before the market opens on Monday, May 13, 2024. John Aballi, Exagen’s President and Chief Executiv...